NEWS
How to protect yourself – COVID-19 (Novel Coronavirus)
A friendly reminder from Your HAEi Team HAE International cares deeply about the health and well-being of you and your family as we all are confronted with the COVID-19 (novel coronavirus) pandemic. Therefore, we have [...]
News from Asia Pacific
From Regional Patient Advocate Fiona Wardman I attended and presented at the Third Scientific Congress of APSID during February in Chandigarh, India. While there, I met with patients and the administrative team from HAE India. [...]
News from Sub-Sahara Africa
From Regional Patient Advocate Patricia Karani I am involved in an exciting HAE International pilot project in Rwanda with a dedicated doctor to locate patients with HAE who have been misdiagnosed. I have established contact [...]
News from Mediterranean & Maghreb countries
From Regional Patient Advocate Maria Ferron During the last few months, my focus has been on the organizing of the 2020 HAEi Regional Workshop North Africa in Algeria, on 6-8 March. This meeting brought together [...]
News from South America & Mexico
From Regional Patient Advocate Fernanda De Oliveira Martins I have held calls with member organization leaders in my region, which have been very successful. So far, the participants have included leaders from Brazil, Colombia, Mexico, [...]
News from Southeastern Europe
From Regional Patient Advocate Natasa Angjeleska In Croatia, I have been assisting and advising the national patient group, which was officially founded on 29 February. HAE Croatia drew some media attention and appeared on several [...]
News from Central Eastern Europe, Middel East & Gulf Region
From Regional Patient Advocate Michal Rutkowski I organized and held Regional Workshops in Wroclaw and Lodz, Poland, during February. Together with HAE Ukraine, I have been working on preparations for the national summit to be [...]
News from Caribbean and Central America
From Regional Patient Advocate Javier Santana I have held discussions with a pharma company from Costa Rica who wishes to introduce a generic HAE treatment to Costa Rica, Guatemala, and Peru. The company is currently [...]
KalVista expects clinical trial delay due to COVID-19
“The Phase 2 clinical trial for KVD900 as an on-demand oral therapy for HAE attacks remains active, but we anticipate a delay in timing of data due to the unprecedented worldwide impact of COVID-19”, says [...]
Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19 Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring and [...]
Global Perspectives #1 2020 out now
The first 2020 issue of the HAE International magazine Global Perspectives – your ultimate source of HAE information globally – is now out. This time you will, among many other items, find articles on [...]
Increased demand for Ruconest
Sijmen de Vries, CEO and Chairman of Pharming Group N.V. in the 2019 Annual Report: "During 2019, we have seen an increase both in patients who are badly affected by HAE and those with less [...]
Let’s join for 2020 HAE Global Walk
Today is 1 April 2020 – and that marks the beginning of this year’s HAE Global Walk. Due to coronavirus COVID-19, the population in a large number of countries around the world experience harsh limitations [...]
EMA validates application for oral HAE medication
The European Medicines Agency (EMA) has validated the marketing authorization application (MAA) submission for approval of oral, once-daily berotralstat (BCX7353) for the prevention of HAE attacks. With this validation, the EMA has begun their formal [...]
Ruconest recommended for acute treatment of children
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicine Agency (EMA) has recommended approval of Ruconest for the treatment of acute angioedema attacks in children with HAE. This marketing authorization would [...]
Information about COVID-19 and angioedema
Dear HAEi Friends, The health and well-being of our global community is HAEi’s top priority. With that in mind, we asked our medical experts to provide their best thinking regarding the COVID-19 virus health [...]
Message from HAEi president Anthony J. Castaldo
Dear HAEi Friends, On behalf of the HAEi Board of Directors and the entire HAEi team, I would like to extend our heartfelt wishes for the health and safety of you and your families [...]
CANCELLATION: 2020 HAE Global Conference
The health and well-being of everyone in the HAE community is of paramount importance to us! As communicated before, HAE International has been carefully monitoring the developing situation regarding COVID-19 (novel coronavirus). HAEi leadership has been meeting on a [...]
ApeX-2 study: Significantly reduced use of acute on-demand medicine
New data from the APeX-2 trial shows that 150 mg of oral, once-daily berotralstat (BCX7353) for prophylaxis of HAE attacks reduced patients’ monthly use of standard of care (SoC) on-demand medicine by 53.6 percent compared [...]
COVID-19 (novel coronavirus)
The HAE International team continues to meet around the clock and carefully monitor the developing global situation regarding the COVID-19 (novel coronavirus), which now includes the declaration of a pandemic by the World Health Organization. [...]
FDA approval of new facility for expanded Ruconest production
The US Food and Drug Administration (FDA) has approved Pharming Group N.V.’s Prior Approval Supplement to add the new Netherlands production facility of starting material to the Biologics License Application (BLA) to support its lead [...]
KalVista: Oral HAE therapies advancing well
At the release of the financial results for the fiscal third quarter ending 31 January 2020 KalVista Pharmaceuticals, Inc. CEO Andrew Crockett said the ‘work to bring multiple best-in-class oral therapies to patients with HAE is [...]
COVID-19 (novel coronavirus)
As mentioned in the previous communication of 27 February 2020, HAE International is carefully monitoring the developing global situation regarding COVID-19 (novel coronavirus) to the extent that it could affect our upcoming 2020 HAE Global Conference [...]
BioCryst on the way to oral HAE treatment
Announcing the financial results for the full year 2019, BioCryst Pharmaceuticals, Inc. President and CEO Jon Stonehouse says that “2020 is off to a strong start, with NDAs accepted and approvals lined up later this year in [...]
BioMarin expects to begin HAE studies in 2020
BioMarin Pharmaceutical Inc., a global biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions, has announced its financial results for 2019. From the Key Program Highlights: [...]
Stay Tuned
Be the first to know what’s going on in the world of HAE
Upcoming events
Apr 1, 2020 - May 31, 2020
HAE Global Walk 2020
Apr 18, 2020
CANCELLED: HAE Spain (AEDAF): General Assembly and Annual Meeting
May 13, 2020 - May 14, 2020
CANCELLED: HAEi Jakobusweg Walk 2020 - long distance
Germany
May 14, 2020 - May 17, 2020
CANCELLED: HAE Global Conference 2020
Check out our latest newsletters
HAE related topics that might interest you
Global Access Program
Helping to change the lives of patients with hereditary angioedema (HAE) with a medication access program
Global Perspectives
Magazine with timely information on the issues, activities, and events that are relevant to the global HAE community
HAEi Connect Member database
Free, secure online membership database and communications platform for HAEi’s member organizations
Regional Patient Advocates
Constantly strive to improve the situation for HAE friends all over the world – no matter how they are organized
Stay tuned – sign up for our newsletter
BE THE FIRST TO KNOW ABOUT HAE NEWS, TREATMENTS, EVENTS AND RELATED TOPICS